Alabama Oncology

Clinical research site in Birmingham, Alabama · 1600 7TH AVE S, BIRMINGHAM, AL 35233-1711 · (205) 939-5432 · Website

Part of Alabama Oncology

As of July 2026, 7 paid clinical trials are recruiting at Alabama Oncology in Birmingham, Alabama. Active studies at this site cover conditions such as Non-Small Cell Lung Cancer and Hormone Receptor Positive HER-2 Negative Breast Cancer. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 19, 2026.

Recruiting clinical trials at Alabama Oncology (7)

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

for Non-small Cell Carcinoma

133 locations incl. Alabaster

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07144280·Phase 3·Recruiting·Listed Aug 2025

Apply to this trial

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

for Triple Negative Breast Cancer

124 locations incl. Birmingham

Sponsor: Gilead Sciences

Sex: All·Age: 18+

Code: NCT05633654·Phase 3·Recruiting·Listed Dec 2022

Apply to this trial

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

for NSCLC (Non-small Cell Lung Cancer)

43 locations incl. Birmingham

Sponsor: Revolution Medicines, Inc.

Sex: All·Age: 18+

Code: NCT06881784·Phase 3·Recruiting·Listed Mar 2025

Apply to this trial

GEMINI-NSCLC: NSCLC Biomarker Study

for Non-Small Cell Lung Cancer

56 locations incl. Birmingham

Sponsor: Tempus AI

Sex: All·Age: 18+

Code: NCT05236114·Recruiting·Listed Feb 2022

Apply to this trial

TEMPUS ARIES: A Biobank Registry Platform Study in Oncology

for Cancer

24 locations incl. Birmingham

Sponsor: Tempus AI

Sex: All·Age: 18 - 99

Code: NCT06207032·Recruiting·Listed Jan 2024

Apply to this trial

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

for Hormone Receptor Positive HER-2 Negative Breast Cancer

34 locations incl. Birmingham

Sponsor: Puma Biotechnology, Inc.

Sex: All·Age: 18+

Code: NCT06369285·Phase 2·Recruiting·Listed Apr 2024

Apply to this trial

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

for HR+/HER2- Breast Cancer

21 locations incl. Birmingham

Sponsor: BeOne Medicines

Sex: All·Age: 18+

Code: NCT07492641·Phase 3·Recruiting·Listed Mar 2026

Apply to this trial

More research sites in Birmingham

University of Alabama at Birmingham (331 trials)
Children's Hospital of Alabama (39 trials)
University of Alabama (33 trials)
University of Alabama at Birmingham Cancer Center (30 trials)
The University of Alabama at Birmingham (27 trials)
University of Alabama Birmingham (27 trials)
UAB (15 trials)
Children's of Alabama (15 trials)
University of Alabama Hospital (13 trials)
Birmingham VA Medical Center, Birmingham, AL (10 trials)

Explore more

Paid clinical trials in Birmingham, AL · Alabama clinical trials